Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Jean van Wyk

Biographic Data

ID7730473
NAMEJean van Wyk
GIVEN NAMESJean
FAMILY NAMEvan Wyk
SIGNATUREVAN WYK J
AFFILIATIONSViiV Healthcare (United Kingdom)
ORCID0000-0001-5719-7949
VERIFIEDYes
TOTAL WORKS3
TOTAL CITATIONS0
AUTHOR COUNT3
EDITOR COUNT0
FIRST PUBLICATION YEAR2014
LATEST PUBLICATION YEAR2024
H-INDEX0
  • Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase …

    Open Access•Cristina Mussini, Charles Cazanave et al.•ARTICLE•AIDS and Behavior•2024

    SOLAR (NCT04542070; registered 2020-09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months vs. continuing daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) over 12 months. Participants were randomised (2:1) to switch to CAB + RPV LA or to continue BIC/FTC/TAF. Patient-reported endpoints included treatment pr…

  • Barriers to access to care reported by women living with HIV across 27 countries

    Margaret Johnson, Anna Samarina et al.•ARTICLE•AIDS Care•2015

    Increased access to successful antiretroviral therapy (ART) is necessary in order to achieve an AIDS-free generation. Importantly, slightly over half of the people living with HIV are women. Small studies have described many barriers to accessing treatment and care among women living with HIV. This cross-sectional, non-interventional, epidemiological study assessed the prevalence of barriers to accessing care for women living with HIV across 27 c…

  • Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

    Kevin Robertson, Carmen Bayón et al.•ARTICLE•AIDS Care•2014

    CRANIum, a cross-sectional epidemiology study in Western Europe and Canada, was conducted to describe and compare the prevalence of a positive screen for neurocognitive impairment (NCI), depressive symptoms, and anxiety in an HIV-positive population either receiving combination antiretroviral therapy (cART) or who were naive to antiretroviral therapy (ART). HIV-positive patients ≥18 years of age attending a routine medical follow-up visit and abl…

No prominent works on this page.

  • Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

    Kevin Robertson, Carmen Bayón et al.•ARTICLE•AIDS Care•2014

    CRANIum, a cross-sectional epidemiology study in Western Europe and Canada, was conducted to describe and compare the prevalence of a positive screen for neurocognitive impairment (NCI), depressive symptoms, and anxiety in an HIV-positive population either receiving combination antiretroviral therapy (cART) or who were naive to antiretroviral therapy (ART). HIV-positive patients ≥18 years of age attending a routine medical follow-up visit and abl…

  • Barriers to access to care reported by women living with HIV across 27 countries

    Margaret Johnson, Anna Samarina et al.•ARTICLE•AIDS Care•2015

    Increased access to successful antiretroviral therapy (ART) is necessary in order to achieve an AIDS-free generation. Importantly, slightly over half of the people living with HIV are women. Small studies have described many barriers to accessing treatment and care among women living with HIV. This cross-sectional, non-interventional, epidemiological study assessed the prevalence of barriers to accessing care for women living with HIV across 27 c…

  • Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase …

    Open Access•Cristina Mussini, Charles Cazanave et al.•ARTICLE•AIDS and Behavior•2024

    SOLAR (NCT04542070; registered 2020-09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months vs. continuing daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) over 12 months. Participants were randomised (2:1) to switch to CAB + RPV LA or to continue BIC/FTC/TAF. Patient-reported endpoints included treatment pr…

HIV Research and Treatment (3 works) · Medicine (3 works) · Antiretroviral therapy (2 works) · HIV/AIDS Research and Interventions (2 works) · Internal Medicine (2 works) · Psychiatry (2 works) · Viral load (2 works) · Anxiety (1 works) · Cart (1 works) · Cognition (1 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae